Is Teleflex (TFX) Still Below Fair Value As Its Recovery Story Rebuilds?
Teleflex (TFX) stock attracts investor interest after recent performance data shows mixed long term returns alongside a positive 1 year total return, drawing renewed attention to how the medical device maker is currently valued.
See our latest analysis for Teleflex.
With the share price at $131.75, Teleflex has posted a 7.64% year to date share price return and a 17.60% total shareholder return over 1 year. However, multi year total shareholder returns remain significantly weaker, suggesting recent momentum is rebuilding from a low base.
If Teleflex’s move has you rethinking where growth might come from in healthcare, it can be useful to widen the lens and look at other medical technology trends through 40 healthcare AI stocks
Teleflex now trades at a marked discount to one fair value estimate and below the average analyst target, yet the stock’s weaker multi year returns hint at lingering doubts about its resilience. Is that caution still warranted as valuation comes into focus?
Most Popular Narrative: 8.3% Undervalued
With Teleflex last trading at $131.75 and the most followed narrative pointing to a fair value of about $143.67, the gap between price and modelled value is currently modest but clear, and it all comes down to how future growth and margins are expected to play out.
The company's focus on portfolio optimization and potential separation or sale of business segments (e.g., NewCo), with anticipated proceeds deployed for debt paydown and shareholder returns, could unlock value and increase net margins and EPS through a more focused, streamlined operating model.
Curious what sits behind that fair value for Teleflex? The narrative leans on a specific revenue glide path, a sharp earnings reset, and a richer future earnings multiple. The exact mix of growth, margin recovery, and discount rate assumptions may surprise you.
Result: Fair Value of $143.67 (UNDERVALUED)
Have a read of the narrative in full and understand what's behind the forecasts.
However, there are still real pressure points for Teleflex, including ongoing weakness in UroLift and the execution risk associated with integrating the BIOTRONIK Vascular Interventions acquisition.
Find out about the key risks to this Teleflex narrative.
Another View: What Multiples Say About Teleflex
While the narrative and fair value model suggest Teleflex could be undervalued, the picture looks more mixed when you zoom in on simple sales based multiples. Teleflex trades on a P/S of 2.7x, which matches the US Medical Equipment industry average of 2.7x but sits above peer levels at 1.8x.
The fair ratio for Teleflex is 2.2x P/S, below the current 2.7x, which implies the market could move closer to that lower level if sentiment cools or peers stay cheaper. For you as an investor, the question is whether the story justifies paying a richer sales multiple than both peers and that fair ratio benchmark.
See what the numbers say about this price — find out in our valuation breakdown.
Next Steps
Teleflex clearly splits opinion, with recent returns improving while longer term performance and valuation still raise questions. If that mix of concern and optimism resonates, take a closer look at the underlying data and form your own view with 2 key rewards and 3 important warning signs
Looking for more investment ideas beyond Teleflex?
If Teleflex has sharpened your thinking, do not stop here. Broaden your watchlist with fresh ideas sourced from different parts of the market.
- Start hunting for potential value standouts by checking 47 high quality undervalued stocks that meet strict quality and valuation criteria.
- Prioritize resilience by reviewing 78 resilient stocks with low risk scores that pair stronger fundamentals with lower overall risk scores.
- Stay ahead of the crowd by scanning the screener containing 20 high quality undiscovered gems before other investors start paying attention.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com